While Sanofi's list price of Aubagio is set at £13,529 ($22,100) per patient a year, NICE was able to recommend it for the NHS after Sanofi made the drug available at a discount under the patient ...

Aubagio missed its primary objective in the TERIKIDS trial, failing to show a significant improvement over placebo in reducing clinical relapses, although numerically the drug reduced the rate by 34%.